Skip Page Header

Home > Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl 4F-iBF), in the framework of the Council Decision on new psychoactive substances. Risk Assessments.

European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl 4F-iBF), in the framework of the Council Decision on new psychoactive substances. Risk Assessments. Luxembourg: Publications Office of the European Union.

[img]
Preview
PDF (Risk assessment 4F-iBF) - Published Version
1MB

This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Date
July 2018
Pages
55 p.
Publisher
Publications Office of the European Union
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page